JANX013 / Janux Therapeutics - LARVOL DELTA

PSMA-013-001: Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Janux Therapeutics

First-in-human • New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Janux Therapeutics…announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC) (Businesswire) - "The Phase 1 clinical trial (NCT07813637) is a first-in-human, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013 in combination with JANX007 in adult patients with mCRPC."

Trial status • Castration-Resistant Prostate Cancer

PSMA-013-001: Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Janux Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Upcoming Milestones (Businesswire) - "Clinical initiation of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, expected in the second half of 2026. Additional clinical data for JANX007 expected to be announced at a future medical congress in the first half of 2027."

New trial • P1 data • Castration-Resistant Prostate Cancer

Upcoming Milestones (Businesswire) - "(i) Janux expects to provide additional clinical data for JANX007 at a future medical congress in the first half of 2027; (ii) Janux plans to announce an initial clinical update from the Phase 1 study of JANX011 in healthy volunteers in the second half of 2026; (iii) Janux plans to initiate clinical development of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, in the second half of 2026."

New trial • P1 data • Castration-Resistant Prostate Cancer

JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 (Businesswire)

New trial • Castration-Resistant Prostate Cancer